Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Abcam
Abcam
Activities:
Research & Development
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Danaher set to acquire antibody company Abcam
The two companies have entered an agreement whereby Danaher is set to acquire biotechnology company Abcam's shares for $24 per share
Manufacturing
Avacta signs distribution agreement with Abcam
Abcam supplies biological reagents and kits used in a wide range of fields including drug discovery, diagnostics and basic research
Finance
Axol Bioscience and Censo Biotechnologies announce merger
Under the terms of the agreement, Axol CEO, Liam Taylor, and the company’s senior leadership team will take over the management of the combined entity
Finance
Abingdon Health signs co-marketing agreement with Abcam
Under the terms of the agreement, Abcam will be the preferred supplier to Abingdon of gold nanoparticles and custom conjugation reagents and services
Finance
Abcam opens cell engineering facility in Bay Area
This development builds upon Abcam’s previous acquisition of a range of knockout cell lines from Edigene last year
Ingredients
Abcam offers bioactive proteins for drug discovery
Sourcing high-quality proteins with batch-to-batch consistency can be a challenge, as endotoxin levels and/or non-native protein conformations and post-translational modifications can affect safety and performance
Manufacturing
John Baker: life sciences need to address the reproducibility crisis
The head of product innovation at Abcam says it is crucial that the whole industry finds ways to de-risk the route to the patient as early as possible
Subscribe now